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Abstract: With the increasing number of elderly patients the issue of pain management for 
older people is of increasing relevance. The alterations with aging of the neurobiology of pain 
have impacts of pain threshold, tolerance and treatment. In this review the available evidence 
from animal and human experimentation is discussed to highlight the differences between 
young and older subjects along with consideration of how these changes have practical effect 
on drug treatment of pain. Cognitive impairment, physical disability and social isolation can 
also impact on the accessibility of treatment and have to be considered along with the biological 
changes with ageing. Conventional pain therapies, while veriﬁ  ed in younger adults cannot be 
automatically applied to the elderly without consideration of all these factors and in no other 
group of patients is a holistic approach to treatment more important.
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There is little merit in considering the treatment of pain in elderly patients as a separate 
entity unless there are real and practical differences to its management in younger 
subjects. Few would argue that these differences do not exist although the deﬁ  nition of 
when a patient becomes “elderly” is problematical. We all know of “young” patients 
who are physiologically and medically old, while others, although chronologically 
advanced retain the health and constitution of others decades younger.
Clearly many disease states become more common as age advances. These con-
ditions may cause acute illnesses that need operative intervention (leading to pain) 
or may cause more chronic pain related disability. But it is about more than just the 
physical health of the patient. We can see the physiological parameters and results of 
blood screening as we measure them and make alterations to our treatment plans for 
that patient, but can easily forget the other issues that contribute to holistic care. The 
elderly are more likely to have sensory impairments, memory difﬁ  culties and lack of 
social backup that can all interfere with treatment and illness recovery. As educated 
practitioners it is easy for us to suggest treatment which may well have the potential 
for being effective with that patient. However, the patient cannot read the drug label 
which states the dose and dose frequency, cannot open the container because of 
arthritic hands, and cannot get assistance with drug administration because they live 
on their own. Therefore, an awareness of all those factors which accompany ageing 
is signiﬁ  cantly more important than just the knowledge of how pain drug treatments 
differ in the elderly.
As well as increased incidence of illness with advancing years, problems of com-
munication with older patients can arise. Impairment of sight and hearing can have 
obvious consequences. Even more problematical is the patient with dementia. They 
suffer pain as much as anyone else but may lack the cognitive function that allows 
them to communicate their pain or the response to drug intervention. Their reaction Clinical Interventions in Aging 2007:2(4) 638
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to pain may be to exhibit abnormal behaviour which can 
be misconstrued as worsening mental function or aggres-
sion. When dealing with the intricacies of pain diagnosis, 
the inability of the patient to describe the location, duration 
and characterization of their pain can make the diagnostic 
process inﬁ  nitely more difﬁ  cult with obvious repercussions 
on the quality of treatment offered. As with young children, 
imaginative methods of assessing pain may aid correct inter-
pretation and treatment.
Allied to all of this is the issue of accessibility to treat-
ment. In terms of chronic pain, the vast majority of pain clin-
ics are Hospital based and a proportion of the treatments they 
offer are available only in a Hospital environment. With the 
physical disability that can accompany ageing, accessibility 
of these services may be less easy. Perhaps what we need is 
an increased understanding in the Primary Care environment 
that would enable effective treatment to be instituted at home 
and not necessitate Hospital referral.
An aging population
In the year 2000, there were more than 400 million people aged 
65 and over in the world with a projected increase to almost 
1.5 billion by the year 2050 (US Bureau of the Census 2002). 
This represents a fourfold increase compared to the 50 percent 
increase for the global population as a whole (Lunenfeld 2002). 
By that time, it is expected that 25% of these elderly people 
will be over the age of 80. Epidemiological evidence sug-
gests that acute pain is similar across all age groups (Corran 
et al 1997; Helme and Gibson 2002). Chronic pain seems to 
increase in incidence up to the seventh decade, although the 
nature and type of this pain may differ from that found in 
younger people. Naturally, older patients are more likely to 
suffer pain as a result of degenerative diseases, as compared 
to those of less advanced years.
Rustoen et al (2005) mailed 4000 Norwegian citizens 
with a pain and health questionnaire. 19.2% of the 18–39 
year old group reported pain of greater than 3 months dura-
tion, 27.5% of the 40–59 year olds also reported chronic 
pain while the ﬁ  gure was 31.2% in the 60–81 year old group. 
Therefore, in this population group, chronic pain was more 
frequent not only in the old, but also in the middle age group 
when compared to younger adults.
Neural differences in the aged
Animal studies suggest that ageing has a signiﬁ  cant effect on 
aspects of the morphological and functional operation of the 
peripheral nervous system (Khalil et al 1994). A decrease in 
the major myelin proteins contributes to a loss in myelinated 
and unmyelinated nerve ﬁ  bers in the elderly. Axonal atrophy 
is more common observed (Verdu et al 2000) while nerve 
conduction and endoneural blood ﬂ  ow are reduced with 
advancing age contributing to a reduction in peripheral nerve 
function (Verdu et al 2000). Even when regeneration of dam-
aged neurons occurs, these regenerated ﬁ  bers have a smaller 
number of terminal and collateral synapses.
In aged rats, immunochemical studies of the spinal cord 
reveal an increase in mRNA content of the neuropeptide 
tyrosine and galanin in dorsal root ganglia (DRG) neurons. 
These animals have decreased cellular content of calcitonin 
gene-related peptide and substance P compared to younger 
animals, while their levels of somatostatin are similar. The 
labeling intensity for encoding high-afﬁ  nity tyrosine recep-
tors (TrkA, Trk B and Trk C) are decreased in the DRG 
neurons of the aged rats (Bergman et al 1996).
It has also been noted that there is a progressive loss of 
both serotinergic and noradrenergic neurons in the super-
ﬁ  cial lamina of the spinal dorsal horn (Wong et al 1984, 
Laporte et al 1996). These neurons are closely implicated 
in descending bulbospinal inhibitory control, and such 
loss may upset the natural endogenous pain-suppressing 
mechanisms.
At supraspinal levels, there is reduced neurotransmitter 
content expression (Barili et al 1998), decreased metabolic 
turnover and a loss of neurons and dendritic connections 
throughout the cerebral cortex, midbrain and brainstem 
(Pakkenberg and Gundersen 1997). It is inevitable that such 
differences result in a differing incidence, quality and hence 
treatment needs of older patients as compared to younger 
adults.
Effect of age in animal pain models
It is known that levels of the neurotransmitter substance 
P (SP) in the spinal cord are lower in very old rats when 
compared to that in young rats. After peripheral nerve injury, 
immunoreactivity to the SP receptor (NK 1, neurokinin 1 
receptor) increases in the spinal cord ipsilateral to the injury 
and the increase correlates to the development of thermal 
hyperalgesia (Cruce et al 2001).
In rats having an incision inﬂ  icted on one of their paws 
and the consequent mechanical sensitivity and thermal 
responses tested, both young and old rats respond in a similar 
fashion to the thermal stimulus. However, younger animals 
appear to recover more quickly from the mechanical allodynia 
produced by the paw incision when compared to the older rats 
(Ririe et al 2003). This suggests that modulation of A-ﬁ  ber 
mediated sensitization differs in young and old rats.Clinical Interventions in Aging 2007:2(4) 639
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Studies on isolated spinal cord neurons show that 
spontaneous ﬁ  ring rates is higher and the response to thermal 
stimulation are greater in aged as compared to adult rats 
(Chakour et al 1996). Furthermore, the size of the receptive 
ﬁ  eld area of wide-dynamic range neurons is larger and that 
of low-threshold neurons smaller in aged as compared to 
adult rats. The increased nociceptive neuronal activity in 
older rats correlates with the ﬁ  nding that paw withdrawal 
latency is signiﬁ  cantly shorter in aged as compared to adult 
rats following heat stimulation of the paw. This along with the 
previously mentioned loss of serotinergic and noradrenergic 
ﬁ  bers in the spinal dorsal horn of older rats may contribute 
to the apparent diminution of descending inhibitory control 
of nociceptive processing in older animals.
Pickering et al (2006) studied young, old and senescent 
rats using a chronic sciatic nerve constriction model. They 
found that senescent animals were less sensitive to neuro-
pathic pain than old or young rats while these senescent 
animals were more sensitive to acute pain than the other 
groups. All of these ﬁ  ndings conﬁ  rm that from a physi-
ological perspective, deﬁ  nite differences exist between young 
adult and older animals.
So animal responses to pain stimuli may differ when adult 
and aged animals are examined. So too may drug effects. 
We are currently seeing an increasing use of opioids, and 
in particular strong opioids, in the management of chronic 
pain. Analgesic tolerance is a potential complication of such 
opioid use. In rat models tolerance is easy to demonstrate. 
Wang et al (2005) examined rats aged 3 weeks, 3, 6 and 
12 months. Morphine was injected twice daily and the time 
until analgesic tolerance measured (which they deﬁ  ned as 
a 75% reduction in morphine-induced analgesia compared 
to day (1). Tolerance was apparent on the 4th, 10th, 14th 
and 22nd days of morphine treatment, respectively. Plasma 
morphine levels and that of its metabolites did not correlate 
with the differences in tolerance development. One other 
factor that impinges on pain perception is the hormonal 
status of the patient. We have seen that in animal models that 
advancing age does have a noticeable effect. But, particularly 
in the female, age brings about hormonal changes as well 
so that, for example, response to opioid analgesics is similar 
in males to gonadectomized and reproductively senescent 
females but differs to that of reproductively active females 
(Sternberg et al 2004).
Effect of age on human pain models
It is not easy to equate the results of human experimental pain 
tests with actual clinical pain conditions. Experimental pain 
tests examine single modalities of pain whereas in clinical 
pain practice a noxious stimulus often produces pain which 
has different facets.
Perhaps the most clinically relevant issues are around 
those of pain threshold and pain tolerance. Gibson (2003) 
reported that over 50 studies have examined age differences 
in sensitivity to experimentally induced pain and that the 
majority of these studies have focused on pain threshold. 
Twenty one studies reported an increase in pain threshold 
with advancing age, 3 a decrease, and 17 no change. When 
all results are examined meta-analytically, the effect size is 
0.74 (p  0.0005), indicating that there is deﬁ  nite evidence of 
an increase in pain threshold with advancing age. That said, 
there may well be a difference in pain threshold depend-
ing on the type of pain inﬂ  icted. Lautenbacher et al (2005) 
studied 20 young men with an average age of 27.1 years 
and compared then to 20 elderly men with an average age 
of 71.6 years. They found that somatosensory thresholds for 
non-noxious stimuli increased with age whereas pressure 
pain thresholds decreased and heat pain thresholds showed 
no age-related changes. These results are conﬁ  rmed by Lin 
and colleagues (2005) who found that there was a consistent 
relationship between sensory thresholds as measured by 
quantitative sensory testing and age.
When pain tolerance is considered, the 10 studies exam-
ining the effect of age on pain tolerance show a deﬁ  nite 
age-related decrease in willingness to endure very strong 
pain. The decrease in pain tolerance is estimated at −0.45 
(p  0.001) across these studies.
Lasch et al (1997) examined the effect of intraesophageal 
balloon dilatation in healthy young and older adults. The 
volume of air inﬂ  ated into the balloon before report of pain 
was measured. The volume was signiﬁ  cantly higher in the 
older subjects. Indeed, many of the older subjects failed to 
report pain even after maximal balloon inﬂ  ation, in marked 
contrast to the younger patients. It certainly seems, using this 
experimental technique, pain threshold does increase with 
age. But this study also reminds us that pain is not always an 
entirely negative symptom. On many occasions it provides 
timely warning of impending problems. For example, if it 
requires a larger volume within a hollow viscus in an elderly 
patient before pain is experienced as compared to younger 
subjects, then the discomfort caused by an obstructive lesion 
in the bowel, for example, may take longer to become symp-
tomatic in older patients, with all the consequences for the 
treatment and prognosis of the causative lesion. It is also 
clinically apparent that the incidence of silent myocardial 
ischemia increases with age (Lucantoni et al 1997). Whether Clinical Interventions in Aging 2007:2(4) 640
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this is due to an increased pain threshold in the older patient, 
a pain reducing effect of concomitant medication, or the 
effects of an intercurrent illness is debatable, but all probably 
have some effect. Therefore, while our emphasis is on the 
management of pain in the elderly, we should not lose sight 
of the fact that thought must also be given to the absence of 
pain in these patients under circumstances where it would 
normally be present.
Pharmacokinetic alterations
Physiological changes in older people affecting fat mass 
(increased), muscle mass (reduced), and body water (reduced) 
have important effects on drug distribution (Turnheim 
2003; Vuyk 2003). Blood volume may also be reduced 
due to concomitant use of diuretics. With the reduction in 
relative fat mass, those drugs which are highly lipophylic, 
such as fentanyl and lidocaine, can have an increased dura-
tion of effect as less of them are soaked up by fat tissue. 
In contrast water soluble dugs, such as morphine) are less 
efﬁ  ciently distributed and higher plasma concentrations are 
obtained with equivalent doses and so side effects may be 
more frequent.
Free drug availability is signiﬁ  cantly augmented by 
decreases in serum albumin, particularly in those elderly 
patients with chronic disease and malnutrition. Such changes 
increase the potential for adverse effects associated with 
highly protein bound analgesics such as NSAIDs and anti-
epileptic agents such as valproate, phenytoin and carbamaze-
pine. Levels of alpha 1-acid glycoprotein, the serum carrier 
for basic drugs such as meperidine, appear unchanged in 
older people.
With increased age, liver and kidney function decrease 
and they become progressively less efﬁ  cient at drug clear-
ance. Drug half-life, a ratio of the volume of distribution to 
clearance, is notably increased for several benzodiazepine 
and tricyclic antidepressants.
Lipid-soluble drugs such as lidocaine and narcotic analge-
sics are good examples of drugs that undergo signiﬁ  cant ﬁ  rst-
pass metabolism during passage from the gastrointestinal 
tract to the liver. Peak plasma concentrations may rise as may 
the potential for dose-related side effects. This situation is 
further compounded when cardiac output is impaired through 
disease. Highly protein bound drugs are less inﬂ  uenced by 
ﬁ  rst-pass metabolism (Bresler and Bahl 2003).
It seems that hepatic phase I reactions involving oxida-
tion, hydrolysis and reduction appear more strongly altered 
by age than phase II conjugation processes (acetylation, 
glucuronidation, sulfation, and glycine conjugation). In 
general, phase I reactions diminish irrespective of which 
microsomal cytochrome P450 enzyme is involved, although 
interindividual variation can be signiﬁ  cant. Acetaminophen 
and diazepam, both processed through the CYP3A4 and 3A5 
enzyme routes, are metabolized at equal rates irrespective 
of age. Carbamazepine, lidocaine and fentanyl, in contrast, 
are subject to reduced metabolism by the same enzyme 
systems in older patients. Glucuronidation of morphine and 
glutathione conjugation of acetaminophen are examples of 
reduced and unaltered phase II reactions respectively. Age 
appears to have no effect on the frequencies of slow- and 
rapid metabolizing genetic polymorphisms.
The most important pharmacokinetic effect of age is the 
reduction in renal clearance. This can be compounded by 
illnesses which further reduce renal function. This can lead 
to drug toxicity at dosing levels appropriate for a younger 
patient with normal renal function. Drugs with a predominant 
renal mode of excretion, such as gabapentin, can cumulate 
when kidney function fails.
Pharmacodynamic changes
Whether the elderly demonstrate actual changes in intrinsic 
sensitivity at the receptor level is controversial both in terms 
of measurable alterations in receptor numbers and the efﬁ  -
ciency of signal transduction following receptor binding. It 
has been shown that in elderly rats, the number of mu and 
kappa opioid receptor numbers fall, while delta-opioid recep-
tor numbers stay unchanged.
One factor that is of practical concern is that of analgesic 
tolerance when opioid drugs are being used. Buntin-Mushock 
et al (2005) performed a retrospective chart review of 206 
patients who had been prescribed strong opioids. They found 
that younger patients reached a maximum dose of around 
450 mg of oral morphine over a 15 month period, while the 
older patients achieved a maximum dose of around 210 mg 
over 14 months. When discharged from their clinic only the 
older patients actually had a reduction in the visual analogue 
pain scores. They suggest that perhaps older patients have 
less chance of developing opioid analgesic tolerance. From 
a practical perspective, decline in homeostatic counter-regu-
latory mechanisms in older patients create a less forgiving 
background to drug administration and it is clear that older 
patients are less able to regain their original physiological 
steady state after administration of drugs. For example, 
tricyclic antidepressants and opioids can induce orthostatic 
hypotension and precipitate falls and syncope. Homeostatic 
changes increase the risk of gastric irritation and bleeding 
following exposure to NSAIDs and ﬁ  gures would suggest Clinical Interventions in Aging 2007:2(4) 641
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that the risk of gastric bleeding is four times higher in older 
individuals when compared to younger adults.
Effect of age on human clinical pain
Clinical observation would suggest that there is an increased 
incidence of silent myocardial ischemia in elderly patients 
and this exempliﬁ  es the fact that advancing age has an effect 
on pain appreciation. Another example would be the atypical 
presentation of an inﬂ  amed appendix where there may be an 
absence of localized right iliac fossa pain. Differences in the 
neuroanatomy, physiology and biochemistry of the nocicep-
tive pathways may cause alterations in pain perception while 
differences in the pharmacology of drugs in the elderly may 
alter expected responses to these drugs. Further compounding 
these issues is the perception of pain in elderly patients by 
their physicians. Yunus et al (1988) compared elderly and 
young patients with ﬁ  bromyalgia. They found that chronic 
headaches, anxiety, tension, mental stress and poor sleep 
were all les common in elderly patients with this condition. 
But most importantly, in only 17% of the elderly patients 
in the study were the features of ﬁ  bromyalgia recognised 
initially by their physician prior to Rheumatological refer-
ral. Many of these patients were exposed to inappropriate 
corticosteroid treatment in the mistaken belief that they had 
an inﬂ  ammatory condition.
The magnitude of the problem of pain in elderly patients is 
highlighted by ﬁ  gures from Sweden. Here a survey revealed 
that 73% of those older that 77 years had pain while 68% of 
those older than 85 years also suffered with pain (Bratberg 
et al 1996). The incidence of pain in the elderly patient is 
affected by a range of variables which include racial and 
ethnic susceptibility to chronic disease, socioeconomic fac-
tors and to accessibility to health care (Reyes-Gibby et al 
2007).
When one tries to consider individual pain conditions 
then there is a lack of depth of evidence on which to base 
conclusions. For example, in the case of low back pain, when 
consideration is given to evidence in published studies then 
there is a marked under-representation of studies that include 
elderly patients and so ﬁ  rm conclusions cannot be reached 
(Bressler et al 1999; Dionne et al 2006). It is however clear 
that when pain does occur in elderly patients it impacts on 
the overall quality of life of the individual (Salafﬁ   et al 2005). 
Analgesic treatment is therefore desirable remembering that 
the response of elderly patients to drug therapy may differ to 
that of younger individuals. It may be that elderly patients 
require lower dosing of opioid analgesics, have a more rapid 
response to them and develop analgesic tolerance more 
slowly than those of less advanced years (Buntin-Mushock 
2005).
Along with aging comes and increased incidence of con-
ditions such as Alzheimer’s disease. It has been observed that 
the use of non-steroidal anti-inﬂ  ammatory drugs is lower in 
patients with this condition than those of a similar age without 
it, and the use of anti-inﬂ  ammatories is not dependent on the 
stage of the Alzheimer’s disease (Scherder and Bouma 1997). 
When patients with Alzheimer’s disease and age matched 
controls are again considered, those with acute pain consume 
a similar quantity of pain killers to non-Alzheimer’s sufferers, 
and it is only in those with chronic pain that consumption is 
signiﬁ  cantly lower (Pickering et al 2006). In contrast, patients 
with vascular dementia seem to suffer more pain than others 
without cognitive impairment due to this condition (Scherder 
et al 2003). As well as differences in pain experience and 
analgesic use, cognitive impairment can also lead to a sig-
niﬁ  cant under-reporting of pain related conditions. Indeed 
Corali et al (2006) found that 41.4% of patients admitted to a 
Geriatric Evaluation and Rehabilitation Unit had previously 
undiagnosed osteoarthritis.
Overall, therefore, as age advances the incidence of pain 
causing conditions differs to that of younger patients, impact 
on quality of life may be greater and a differing response to 
analgesic intervention may be observed.
Drug treatment
An increasing number of consensus statements are being 
published by professional groups suggesting pharmacological 
strategies for providing pain relief. While these represent a 
useful formalization of available evidence, they have a strong 
tendency to suggest medications which have a deﬁ  nite indica-
tion for the suggested use. For example, when neuropathic 
pain is considered, gabapentin and pregabalin are prominent 
suggested treatments. These recommendations are based both 
on the fact that they have product licenses for us in neuro-
pathic pain and because there is signiﬁ  cant evidence of effect 
in the general, but not necessarily the elderly, population. If 
patients ability to tolerate drugs decreases and anxieties about 
potential drug–drug interactions increases with advancing 
years, then consideration may need to be given to “off-label” 
use of drugs. When a speciﬁ  c indication is sought for a drug, 
the licensing authorities base their considerations on three 
primary factors. First the physical quality of the preparation. 
Second its safety and third the evidence of its effect in that 
condition. There are, however, many drugs successfully used 
in pain management whose use is “off-label” because the 
practitioner considers the risk to the patient to be less and the Clinical Interventions in Aging 2007:2(4) 642
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chances of alleviating pain greater when that drug is used as 
opposed to a licensed alternative.
For example, osteoarthritis is extremely common in 
elderly patients. Conventional treatment would involve the 
use of non-steroidal anti-inﬂ  ammatory drugs. These may 
be contraindicated in some elderly patients because of heart 
failure, renal failure, concomitant drug use or because of 
previous peptic ulcer disease. Topical nitrates can produce 
marked reduction in inﬂ  ammation and pain (McCleane 
2000a, 2007b). Similarly, amitriptyline is often prescribed 
for neuropathic pain conditions such as postherpetic neural-
gia. Topical tricyclic antidepressants can also have a pain 
reducing effect without the common side effects associated 
with oral tricyclic use (McCleane 2000b, 2007). It may 
well be that the practitioner has to make a valued judgment 
about whether it is in the best interests of the patient to use 
“conventional”, licensed medication, or because of anxieties 
about the patients state of health resultant in their advanced 
age as to whether “off-label” use of drugs with proven pain 
relieving effect may be more appropriate.
Conclusions
Experimental testing in both animals and humans, and indeed 
practical experience conﬁ  rm that the experience of pain, its 
presentation, diagnosis, pathophysiology and actual treatment 
change as age progresses. In one sense the chronological age 
of the patient is not relevant as it gives an artiﬁ  cial estimate 
of the individual’s health status. What is more important 
is how that individual’s health deviates from what may be 
considered average for an adult. In anesthesiological practice, 
for example, the risk of a patient undergoing anesthesia is 
not estimated using age as a criterion. Rather an estimate 
of risk is made using assessment scales, such as the “ASA” 
grading system which classify the patient’s health using the 
presence or absence of disease states, whether these diseases 
are mild or severe and whether they represent a constant 
threat to life.
It could be argued, therefore, that one should not base a 
diagnosis and plan treatment on the basis of that patient’s age 
alone. For all patients, regardless of age, we should have an 
individual approach and construct a diagnostic package and 
treatment plan based on that individual’s situation, taking 
account of their physical and mental health, expectations, 
social circumstances and their general well being.
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